Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer|Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: larotaxel (XRP9881)|DRUG: trastuzumab
Sponsor: Sanofi